Aptose Biosciences(APTO)
搜索文档
Aptose Biosciences(APTO) - 2019 Q4 - Annual Report
2020-03-11 05:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-3200 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada (State or other jurisdiction of incorporation or organization) 98-1136802 (I.R.S. Employer ...
Aptose Biosciences(APTO) - 2019 Q3 - Earnings Call Transcript
2019-11-06 16:43
Aptose Biosciences, Inc. (NASDAQ:APTO) Q3 2019 Earnings Conference Call November 5, 2019 5:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President & CEO Jotin Marango - SVP & Chief Business Officer Gregory Chow - EVP, Corporate Secretary & CFO Conference Call Participants Gregory Renza - RBC Capital Markets John Newman - Canaccord Genuity Corp. Kalpit Patel - Oppenheimer Naureen Quibria - Maxim Group Matthew Cross - JonesTrading Institutional Services Operator ...
Aptose Biosciences(APTO) - 2019 Q3 - Quarterly Report
2019-11-06 06:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada 98-1136802 (State or Other Jurisdiction of I ...
Aptose Biosciences(APTO) - 2019 Q2 - Earnings Call Transcript
2019-08-07 13:01
Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2019 Results Conference Call August 6, 2019 5:00 PM ET Company Participants Susan Pietropaolo - Investor Relations Dr. William Rice - Chairman, President and Chief Executive Officer Gregory Chow - Executive Vice President and Chief Financial Officer Dr. Jotin Marango - Senior Vice President and Chief Business Officer Conference Call Participants Gregory Windsor - RBC Capital Markets John Newman - Canaccord Genuity Matthew Biegler - Oppenheimer Matthew Cross - Jones T ...
Aptose Biosciences(APTO) - 2019 Q2 - Quarterly Report
2019-08-07 05:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30 , 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada 98-1136802 (State or Other Jurisdiction of Incor ...
Aptose Biosciences(APTO) - 2019 Q1 - Quarterly Report
2019-05-08 04:47
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-35447 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada 98-1136802 (State or Other Jurisdiction of Incor ...